SESN
Sesen Bio Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2020, the Company completed the BLA submission for Vicineum to the FDA. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China and the Middle East and North Africa (MENA), for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.
Market Cap: 119 Million
Primary Exchange: NASDAQ
Website: www.sesenbio.com
Shares Outstanding: 203 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.0
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1581 trading days
From: 2018-05-03 To: 2023-03-06
Lowest Point:
Sesen Bio (SESN) Investor Presentation - Slideshow
via: SeekingAlpha at 2019-06-11 10:44:23:000
The following slide deck was published by Sesen Bio, Inc. in conjunction with this Read more … read more...
Sesen Bio (SESN) Investor Presentation - Slideshow
via: SeekingAlpha at 2019-06-11 10:44:23:000
The following slide deck was published by Sesen Bio, Inc. in conjunction with this Read more … read more...
Sesen Bio (SESN) Investor Presentation - Slideshow
via: SeekingAlpha at 2019-06-11 10:44:23:000
The following slide deck was published by Sesen Bio, Inc. in conjunction with this Read more … read more...
Sesen Bio up 8% premarket on successful Pre-BLA meeting for Vicinium
via: SeekingAlpha at 2019-06-10 03:30:33:000
Sesen Bio (NASDAQ: SESN ) has completed a successful Type B Pre-BLA meeting regarding the approval path for Vicinium for the treatment of patients with Bacillus Calmette-Gurin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). More news on: Sesen Bio, Inc., Healthcare … read more...
Sesen Bio Announces Successful Pre-BLA Meeting with FDA for Vicinium®
via: Business Wire at 2019-06-10 03:00:00:000
FDA Recommends Accelerated Approval Pathway FDA Indicated No Additional Clinical Trials Necessary for BLA Submission Company Expects to Initiate Submission of the BLA in 4Q 2019 Under Rolling Review Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing target… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|---|---|---|---|---|---|---|---|
| 2023-03-06 | 2023-03-07 | 2023-03-02 | 0.361 | Cash&Stock | ||||
| 2023-03-08 | 2023-03-08 | 2023-03-07 | 2023-03-02 | 0.361 | Cash&Stock |
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|